BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 17388661)

  • 1. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
    Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
    PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers.
    Nakamura Y; Oshima K; Naoi Y; Nakayama T; Kim SJ; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
    Breast Cancer Res Treat; 2012 Jul; 134(1):229-36. PubMed ID: 22315133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
    Kandioler-Eckersberger D; Ludwig C; Rudas M; Kappel S; Janschek E; Wenzel C; Schlagbauer-Wadl H; Mittlböck M; Gnant M; Steger G; Jakesz R
    Clin Cancer Res; 2000 Jan; 6(1):50-6. PubMed ID: 10656431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 in breast cancer subtypes and new insights into response to chemotherapy.
    Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
    Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.
    Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S
    Cancer; 2011 Aug; 117(16):3682-90. PubMed ID: 21305539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting.
    Petit T; Borel C; Ghnassia JP; Rodier JF; Escande A; Mors R; Haegelé P
    Clin Cancer Res; 2001 Jun; 7(6):1577-81. PubMed ID: 11410493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
    Berns EM; Klijn JG; Look MP; Grebenchtchikov N; Vossen R; Peters H; Geurts-Moespot A; Portengen H; van Staveren IL; Meijer-van Gelder ME; Bakker B; Sweep FC; Foekens JA
    Clin Cancer Res; 2003 Apr; 9(4):1253-8. PubMed ID: 12684392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy for Chinese women with locally advanced breast cancer.
    Chow LW; Day W; Ng KC
    Am Surg; 2001 May; 67(5):412-6. PubMed ID: 11379638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
    Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
    Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.
    Lehmann-Che J; André F; Desmedt C; Mazouni C; Giacchetti S; Turpin E; Espié M; Plassa LF; Marty M; Bertheau P; Sotiriou C; Piccart M; Symmans WF; Pusztai L; de Thé H
    Oncologist; 2010; 15(3):246-52. PubMed ID: 20228131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neoadjuvant chemotherapy for primary breast cancer].
    Li JF; Ouyang T; Wang TF; Lin BY
    Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):493-5. PubMed ID: 15555342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.
    Perrone F; Bossi P; Cortelazzi B; Locati L; Quattrone P; Pierotti MA; Pilotti S; Licitra L
    J Clin Oncol; 2010 Feb; 28(5):761-6. PubMed ID: 20048189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of breast cancer prognosis by gene expression profile of TP53 status.
    Takahashi S; Moriya T; Ishida T; Shibata H; Sasano H; Ohuchi N; Ishioka C
    Cancer Sci; 2008 Feb; 99(2):324-32. PubMed ID: 18271932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 as a specific prognostic factor in triple-negative breast cancer.
    Chae BJ; Bae JS; Lee A; Park WC; Seo YJ; Song BJ; Kim JS; Jung SS
    Jpn J Clin Oncol; 2009 Apr; 39(4):217-24. PubMed ID: 19304743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
    Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.